For years, companies have been rewarded with exclusive incentives for developing complex biologic drugs, but a new analysis finds the median development times between these medicines and simpler-to-build small-molecule drugs were no different. And the researchers suggested the rewards given to biologic makers may be misplaced.

Using what they called a novel approach to analyzing patent databases, the researchers looked at 275 new drugs approved by the Food and Drug Administration between 2007 and 2016. Of those, 77% were small-molecule drugs and 23% were biologics, but the median total development times — from the first patent filing to FDA approval — was 12.4 years both types of medicines.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

Your daily dose of news in health and medicine

Privacy Policy